A case of minimal change disease treated successfully with mycophenolate mofetil in a patient with systemic lupus erythematosus.
The World Health Organization classifies lupus nephritis as class I to V or VI. However, a few cases of minimal change glomerulopathy have been reported in association with systemic lupus erythematosus (SLE). Mycophenolate mofetil has been shown to be effective for treatment of minimal change disease and lupus nephritis. A 24-year-old woman diagnosed with SLE five years prior to presentation complained of a mild generalized edema. The urinalysis showed microscopic hematuria and proteinuria. The assessed amount of total proteinuria was 1,618 mg/24 hours. A renal biopsy demonstrated diffuse fusion of the foot processes of podocytes on electron microscopy. Mycophenolate mofetil was started in addition to the maintenance medications of prednisolone 10 mg/day and hydroxychloroquine 400 mg/day. After six months of treatment, the microscopic hematuria and proteinuria resolved, and the total urine protein decreased to 100 mg/24 hours.
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Young Hoon
YH
Hong
Dae Young
DY
Yun
Yong Wook
YW
Jung
Myung Jin
MJ
Oh
Hyun Je
HJ
Kim
Choong Ki
CK
Lee
D018501:Antirheumatic Agents / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000473:pathology*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009402:Nephrosis, Lipoid / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D055815:Young Adult
D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D006886:Hydroxychloroquine; D009173:Mycophenolic Acid; D011241:Prednisone